MedPath

Precise Percutaneous Coronary Intervention Plan (P3) Study

Completed
Conditions
Stable Coronary Artery Disease
Interventions
Diagnostic Test: FFRCT planner
Registration Number
NCT03782688
Lead Sponsor
Onze Lieve Vrouw Hospital
Brief Summary

The PRECISE PERCUTANEOUS CORONARY INTERVENTION (PCI) PLAN STUDY is an investigator-initiated, international and multicenter study of patients with an indication for PCI aiming at assessing the agreement and accuracy of the HeartFlow Planner with invasive fractional flow reserve (FFR) as a reference.

Detailed Description

Multicenter study, including 120 patients at 5 centers in Europe and Asia. After identifying the presence of significant coronary stenosis by means of coronary angiography and invasive fractional flow reserve (FFR≤0.80) the patients will undergo the following procedures: Invasive FFR with intravenous adenosine (i.e. pre- and post-PCI). Optical coherence tomography-guided PCI (i.e. pre- and post-procedural imaging). PCI with newer generation drug-eluting stent.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
127
Inclusion Criteria
  • Coronary artery disease in a major epicardial vessel with an invasive fractional flow reserve (FFR) ≤0.80
  • An indication to Percutaneous coronary intervention
Exclusion Criteria
  • Angiographic exclusion criteria
  1. Severely calcified lesion/vessel
  2. Bifurcation lesions.
  3. Ostial lesions.
  4. Left main disease.
  5. Severe vessel tortuosity.

Clinical exclusion criteria

  1. Chronic obstructive pulmonary disease

  2. Contraindication to adenosine

  3. NYHA class III or IV, or last known left ventricular ejection fraction <30%

  4. Uncontrolled or recurrent ventricular tachycardia

  5. Atrial fibrillation, flutter or arrhythmia

  6. History of recent stroke (≤90 days)

  7. History of acute coronary syndrome (≤90 days)

  8. Prior myocardial infarction

  9. History of ischemic stroke (>90 days) with modified RANKIN score ≥ 2

  10. History of any hemorrhagic stroke

  11. Previous revascularization (PCI or Coronary artery bypass grafting)

  12. Active liver disease or hepatic dysfunction, defined as AST or ALT > 3 times the ULN

  13. Severe renal dysfunction, defined as an eGFR <30 mL/min/1.73 m2

  14. Body mass index>35 kg/m2

  15. Nitrate intolerance

  16. Contra-indication to heart rate lowering drugs

    Imaging-related

  17. Insufficient coronary CT Angiography image quality.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Single-arm cohortFFRCT plannerPatients with significant coronary stenosis by invasive fractional flow reserve (FFR≤0.80)
Primary Outcome Measures
NameTimeMethod
Agreement on post-PCI fractional flow reserve between virtual treatment based on FFRct planner and measured invasive post-PCI fractional flow reserve.The primary endpoint will be assessed immediately after the procedure (PCI).

The agreement will be assessed by Bland Altman method

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

OLV-Aalst

🇧🇪

Aalst, Oost-Vlaanderen, Belgium

© Copyright 2025. All Rights Reserved by MedPath